<DOC>
	<DOCNO>NCT00305773</DOCNO>
	<brief_summary>Vorinostat may stop growth cancer cell block enzyme need growth . Giving drug different way may kill cancer cell . This randomized phase II trial study two different schedule vorinostat see well work treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Vorinostat Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine toxicity proportion complete remission associate two different treatment schedule vorinostat ( SAHA ) patient acute myeloid leukemia . SECONDARY OBJECTIVES : I . Determine toxic effect SAHA study population . II . Examine preliminary evidence re-expression silence gene leukemic blast response SAHA . OUTLINE : This multicenter , randomize study . Patients stratify accord disease status ( relapse vs untreated ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive oral vorinostat ( SAHA ) day day 1-21 . In arm , treatment repeat every 21 day 17 course absence disease progression unacceptable toxicity . ARM II : Patients receive oral SAHA three time day day 1-14 . In arm , treatment repeat every 21 day 17 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 44 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( AML ) , meet 1 follow criterion : Relapsed AML follow category : Goodrisk cytogenetics [ inv ( 16 ) , ( 8 ; 21 ) ] second relapse first relapse follow remission &lt; 12 month Acute promyelocytic leukemia ( M3 ) second relapse great AND must relapse follow tretinoinanthracyclinebased therapy arsenic trioxidebased therapy All relapse patient eligible Untreated AML follow category : At least 65 year age Myelodysplastic syndromesAML ( AML trilineage dysplasia ) AML del5Q monosomy 5 , monosomy 7 , complex cytogenetics ( ≥ 3 cytogenetic abnormality ) Refused ineligible potentially curative option allogeneic stem cell transplantation No clinical evidence CNS pulmonary leukostasis , disseminate intravascular coagulation , CNS leukemia ECOG performance status ( PS ) 02 Karnofsky PS ≥ 60 % Life expectancy ≥ 3 month Bilirubin normal unless attribute hemolysis Gilbert 's disease opinion investigator AST/ALT ≤ 2.5 time upper limit normal ( ULN ) Creatinine normal OR creatinine clearance ≥ 60 mL/min No history allergic reaction attribute compound similar chemical biologic composition vorinostat No uncontrolled intercurrent illness , include follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known HIV positivity More 4 week since prior radiotherapy More 2 week since prior valproic acid More 3 week since prior treatment AML , include hematopoietic growth factor Hydroxyurea WBC &gt; 30,000/mm^3 allow Recovered prior therapy No concurrent filgrastim ( GCSF ) , sargramostim ( GMCSF ) , epoetin alfa , darbepoetin alfa No concurrent investigational agent No concurrent anticancer agent therapy cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>